ARTICLE | Company News
MabCure, CUNY for Advanced Technology Development deal
March 26, 2012 7:00 AM UTC
The center will evaluate and validate MabCure's mAbs as diagnostic reagents for ovarian cancer. The mAbs are in preclinical testing. Details were not disclosed. ...